

Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Plasma Triglycerides in Hypertriglyceridemia

Circulation

140, 470-486

DOI: [10.1161/circulationaha.118.039107](https://doi.org/10.1161/circulationaha.118.039107)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The Future of Lipid-lowering Therapy. <i>Journal of Clinical Medicine</i> , 2019, 8, 1085.	1.0	8
2	A new dawn for managing dyslipidemias: The era of rna-based therapies. <i>Pharmacological Research</i> , 2019, 150, 104413.	3.1	70
3	Investigational drugs in development for hypertriglyceridemia: a coming-of-age story. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 1059-1079.	1.9	3
4	Angiotensin-like proteins as therapeutic targets for cardiovascular disease: focus on lipid disorders. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 79-88.	1.5	40
5	Hypertriglyceridemiaâ€”Causes, Significance, and Approaches to Therapy. <i>Frontiers in Endocrinology</i> , 2020, 11, 616.	1.5	29
6	Triglycerides, HDL cholesterol and atherogenic dyslipidaemia in the 2019 European guidelines for the management of dyslipidaemias. <i>ClÃnica E InvestigaciÃn En Arteriosclerosis (English Edition)</i> , 2020, 32, 209-218.	0.1	2
7	Angiotensin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance. <i>Journal of Lipid Research</i> , 2020, 61, 1271-1286.	2.0	120
8	Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1675-1684.	0.9	17
9	A Comprehensive Update on the Chylomicronemia Syndrome. <i>Frontiers in Endocrinology</i> , 2020, 11, 593931.	1.5	60
10	Statin therapy reduces plasma angiotensin-like 3 (ANGPTL3) concentrations in hypercholesterolemic patients via reduced liver X receptor (LXR) activation. <i>Atherosclerosis</i> , 2020, 315, 68-75.	0.4	8
11	Angiotensin-like protein 3, an emerging cardiometabolic therapy target with systemic and cell-autonomous functions. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2020, 1865, 158791.	1.2	13
12	Familial Chylomicronemia Syndrome (FCS): Recent Data on Diagnosis and Treatment. <i>Current Atherosclerosis Reports</i> , 2020, 22, 63.	2.0	21
13	Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to <i>ANGPTL3</i> mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. <i>European Heart Journal</i> , 2020, 41, 3936-3945.	1.0	188
14	Evinacumab for Homozygous Familial Hypercholesterolemia. <i>New England Journal of Medicine</i> , 2020, 383, 711-720.	13.9	413
15	TriglicÃ©ridos, colesterol HDL y dislipidemia aterogÃ©nica en la guÃa europea para el control de las dislipidemias 2019. <i>ClÃnica E InvestigaciÃn En Arteriosclerosis</i> , 2020, 32, 209-218.	0.4	3
16	A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects. <i>Atherosclerosis</i> , 2020, 314, 33-40.	0.4	27
17	Genomic Strategies Toward Identification of Novel Therapeutic Targets. <i>Handbook of Experimental Pharmacology</i> , 2020, , 1.	0.9	3
18	Regulation of lipoprotein lipase-mediated lipolysis of triglycerides. <i>Current Opinion in Lipidology</i> , 2020, 31, 154-160.	1.2	67

#	ARTICLE	IF	CITATIONS
19	Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials. <i>Current Atherosclerosis Reports</i> , 2020, 22, 18.	2.0	26
20	Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions. <i>Current Atherosclerosis Reports</i> , 2020, 22, 25.	2.0	38
21	Angiotensin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids. <i>Journal of Lipid Research</i> , 2020, 61, 1203-1220.	2.0	88
22	Reducing residual cardiovascular risk with novel therapies. <i>Current Opinion in Lipidology</i> , 2020, 31, 108-110.	1.2	7
23	Familial combined hypolipidemia: angiotensin-like protein-3 deficiency. <i>Current Opinion in Lipidology</i> , 2020, 31, 41-48.	1.2	28
24	Low cholesterol syndrome and drug development. <i>Current Opinion in Cardiology</i> , 2020, 35, 423-427.	0.8	1
25	Nucleic Acid-Based Therapies for Atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2020, 22, 10.	2.0	22
26	Unfolding of monomeric lipoprotein lipase by ANGPTL4: Insight into the regulation of plasma triglyceride metabolism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 4337-4346.	3.3	56
27	Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia. <i>Pharmacological Research</i> , 2020, 153, 104653.	3.1	54
28	ANGPTL3, PCSK9, and statin therapy drive remarkable reductions in hyperlipidemia and atherosclerosis in a mouse model. <i>Journal of Lipid Research</i> , 2020, 61, 272-274.	2.0	7
29	The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiotensin like protein 3 reduce cardiovascular disease?. <i>Current Opinion in Lipidology</i> , 2020, 31, 140-146.	1.2	29
30	Emerging lipid lowering agents targeting LDL cholesterol. <i>Postgraduate Medicine</i> , 2020, 132, 433-440.	0.9	5
31	Postprandial hyperlipidemia as a risk factor in patients with type 2 diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , 2020, 15, 147-157.	1.2	12
32	Biotechnology Approaches for the Treatment of Dyslipidemia. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 167-183.	1.3	4
33	New Approaches for the Prevention and Treatment of Cardiovascular Disease: Focus on Lipoproteins and Inflammation. <i>Annual Review of Medicine</i> , 2021, 72, 431-446.	5.0	9
34	Will evinacumab become the standard treatment for homozygous familial hypercholesterolemia?. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 299-302.	1.4	5
35	Enzymes Lipoprotein Lipase. , 2021, , 307-320.		0
36	Angiotensin-like proteins inhibitors: New horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia. <i>Cardiology Journal</i> , 2023, 30, 131-142.	0.5	9

#	ARTICLE	IF	CITATIONS
37	Severe insulin resistance syndromes. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	35
38	Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of <i>Angptl3</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	192
40	ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets. <i>Current Atherosclerosis Reports</i> , 2021, 23, 20.	2.0	36
41	ANGPLT3 in cardio-metabolic disorders. <i>Molecular Biology Reports</i> , 2021, 48, 2729-2739.	1.0	9
42	Genetics of Triglyceride-Rich Lipoproteins Guide Identification of Pharmacotherapy for Cardiovascular Risk Reduction. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 677-690.	1.3	11
43	Triglycerides and cardiovascular disease. <i>Current Opinion in Cardiology</i> , 2021, 36, 469-477.	0.8	19
44	Maternal Serum Angiotensin-Like 3 Levels in Healthy and Mild Preeclamptic Pregnant Women. <i>Frontiers in Endocrinology</i> , 2021, 12, 670357.	1.5	3
45	Umbrella Review on Non-Statins Lipid-Lowering Therapy. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 107424842110029.	1.0	11
46	Liver-targeting drugs and their effect on blood glucose and hepatic lipids. <i>Diabetologia</i> , 2021, 64, 1461-1479.	2.9	21
47	Targeted Therapy in Cardiovascular Disease: A Precision Therapy Era. <i>Frontiers in Pharmacology</i> , 2021, 12, 623674.	1.6	12
48	A compass for navigating the perils of hypertriglyceridaemia. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 248-249.	5.5	1
49	A case of homozygous familial hypercholesterolemia with an atypical phenotype and delayed clinical symptoms. <i>Journal of Clinical Lipidology</i> , 2021, 15, 435-440.	0.6	0
50	A lipid lover's guide to novel therapeutics for lipid and cardiovascular risk reduction. <i>Future Cardiology</i> , 2021, 17, 507-520.	0.5	2
51	Targeting angiotensin-like 3 in atherosclerosis: From bench to bedside. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2020-2034.	2.2	10
52	The Genetic Basis of Hypertriglyceridemia. <i>Current Atherosclerosis Reports</i> , 2021, 23, 39.	2.0	17
53	Inclisiran "Silencing the Cholesterol, Speaking up the Prognosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2467.	1.0	14
54	Biologic therapy for dyslipidemia. <i>Vnitřní Lekarství</i> , 2021, 67, 206-211.	0.1	1
55	Novel RNAi-Based Therapies for Atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2021, 23, 45.	2.0	13

#	ARTICLE	IF	CITATIONS
56	Angiotensin-like protein 3 inhibitors and contemporary unmet needs in lipid management. <i>Current Opinion in Lipidology</i> , 2021, 32, 210-212.	1.2	3
57	Managing dyslipidemia in patients with Type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2221-2234.	0.9	14
58	Inhibition of Angiotensin-Like Protein 3 With Evinacumab in Subjects With High and Severe Hypertriglyceridemia. <i>Journal of the American College of Cardiology</i> , 2021, 78, 193-195.	1.2	36
59	Angiotensin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7310.	1.8	26
60	Highlights from Studies Presented at the Virtual American College of Cardiology Scientific Sessions 2021: Staying Updated with the Latest Advancements in Prevention. <i>Current Atherosclerosis Reports</i> , 2021, 23, 50.	2.0	7
61	The Importance of Lipoprotein Lipase Regulation in Atherosclerosis. <i>Biomedicines</i> , 2021, 9, 782.	1.4	33
62	Evinacumab for treatment of familial hypercholesterolemia. <i>Expert Review of Cardiovascular Therapy</i> , 2021, 19, 739-751.	0.6	6
63	Coronary Artery Disease Genetics Enlightened by Genome-Wide Association Studies. <i>JACC Basic To Translational Science</i> , 2021, 6, 610-623.	1.9	47
64	Human Angiotensin-like Protein 3/ANGPTL3 Antibodies. <i>Journal of Cardiovascular Pharmacology</i> , 2021, Publish Ahead of Print, e631-e640.	0.8	0
65	Dyslipidemia in Patients with Kidney Disease. <i>Cardiology Clinics</i> , 2021, 39, 353-363.	0.9	14
66	Potential of Phage Display Antibody Technology for Cardiovascular Disease Immunotherapy. <i>Journal of Cardiovascular Translational Research</i> , 2022, 15, 360-380.	1.1	4
67	A quantitative systems pharmacology modeling platform for evaluating triglyceride profiles in patients with high triglycerides receiving evinacumab. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1332-1342.	1.3	2
68	Case Studies in Pediatric Lipid Disorders and Their Management. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 3605-3620.	1.8	4
69	Efficacy and Safety of Evinacumab for the Treatment of Hypercholesterolemia: A Meta-Analysis. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 78, 394-402.	0.8	11
70	Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis. <i>Current Atherosclerosis Reports</i> , 2021, 23, 72.	2.0	19
71	A VLP-based vaccine targeting ANGPTL3 lowers plasma triglycerides in mice. <i>Vaccine</i> , 2021, 39, 5780-5786.	1.7	13
72	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society. <i>European Heart Journal</i> , 2021, 42, 4791-4806.	1.0	303
73	The Lipid-Modulating Effect of Tazemetan on the Inhibition of Angiotensin-like 3 (ANGPTL3) Gene Expression through Regulation of LXR α Activation in Hepatic Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9853.	1.8	14

#	ARTICLE	IF	CITATIONS
74	Population pharmacokinetics and exposureâ€“response modeling for evinacumab in homozygous familial hypercholesterolemia. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1412-1421.	1.3	4
75	ANGPTL3 as therapeutic target. <i>Current Opinion in Lipidology</i> , 2021, 32, 335-341.	1.2	34
76	Rare Treatments for Rare Dyslipidemias: New Perspectives in the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) and Familial Chylomicronemia Syndrome (FCS). <i>Current Atherosclerosis Reports</i> , 2021, 23, 65.	2.0	16
77	Current Diagnosis and Management of Primary Chylomicronemia. <i>Journal of Atherosclerosis and Thrombosis</i> , 2021, 28, 883-904.	0.9	14
78	Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021, 321, E493-E508.	1.8	42
79	Evinacumab â€“ The new kid on the block. Is it important for cardiovascular prevention?. <i>International Journal of Cardiology Cardiovascular Risk and Prevention</i> , 2021, 11, 200107.	0.4	5
80	The Clinical Role of Angiotensin-Like Protein 3 in Evaluating Coronary Artery Disease in Patients with Obstructive Sleep Apnea. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 773-780.	1.3	10
81	Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapiesâ€“a Clinical Perspective. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 1269-1279.	1.3	13
82	Apolipoprotein C-II: the re-emergence of a forgotten factor. <i>Current Opinion in Lipidology</i> , 2020, 31, 147-153.	1.2	33
83	Emerging Strategies for the Management of Atherogenic Dyslipidaemia. <i>European Cardiology Review</i> , 2020, 15, 1-3.	0.7	6
84	New Therapies for Lowering Triglyceride-Rich Lipoproteins. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1817-1830.	1.2	28
85	Novel therapeutic targets and agents for pediatric dyslipidemia. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021, 12, 204201882110583.	1.4	4
86	The year in cardiovascular medicine 2021: dyslipidaemia. <i>European Heart Journal</i> , 2022, , .	1.0	9
87	Lean adolescents with insulin resistance display higher angiotensin like protein 3, ApoC-III and chylomicron remnant dyslipidemia. <i>Clinica Chimica Acta</i> , 2022, 526, 43-48.	0.5	8
88	Cholesterol-Lowering Drugs. , 2020, , 233-248.		0
89	Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales. <i>Frontiers in Pharmacology</i> , 2021, 12, 807548.	1.6	64
90	Childhood Hypertriglyceridemia: Is It Time for a New Approach?. <i>Current Atherosclerosis Reports</i> , 2022, 24, 265-275.	2.0	3
91	Friend or foe for obesity: how hepatokines remodel adipose tissues and translational perspective. <i>Genes and Diseases</i> , 2022, , .	1.5	0

#	ARTICLE	IF	CITATIONS
92	Therapeutic RNA-silencing oligonucleotides in metabolic diseases. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 417-439.	21.5	24
93	Evinacumab for the treatment of homozygous familial hypercholesterolemia. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 139-145.	1.3	3
95	A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?. <i>BioDrugs</i> , 2022, 36, 121-135.	2.2	9
96	An anti-ANGPTL3/8 antibody decreases circulating triglycerides by binding to a LPL-inhibitory leucine zipper-like motif. <i>Journal of Lipid Research</i> , 2022, 63, 100198.	2.0	23
97	Hepatokines and Non-Alcoholic Fatty Liver Disease: Linking Liver Pathophysiology to Metabolism. <i>Biomedicines</i> , 2021, 9, 1903.	1.4	16
98	New Therapies for Primary Hyperlipidemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1216-1224.	1.8	21
99	New therapeutic approaches for the treatment of hypertriglyceridemia. <i>Herz</i> , 2022, 47, 220-227.	0.4	3
100	The Functional Role of Lipoproteins in Atherosclerosis: Novel Directions for Diagnosis and Targeting Therapy. , 2022, 13, 491.		17
101	The promising novel therapies for familial hypercholesterolemia. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, .	0.9	12
102	Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 813-820.	1.4	6
103	The Regulation of Triacylglycerol Metabolism and Lipoprotein Lipase Activity. <i>Advanced Biology</i> , 2022, 6, .	1.4	13
104	RNA interference-based therapies for the control of atherosclerosis risk factors. <i>Current Opinion in Cardiology</i> , 2022, 37, 364-371.	0.8	2
105	Triglyceride-Rich Lipoproteins, Remnants, and Atherosclerotic Cardiovascular Disease Risk. <i>Current Cardiovascular Risk Reports</i> , 0, , .	0.8	0
106	Lipid Lowering Therapy: An Era Beyond Statins. <i>Current Problems in Cardiology</i> , 2022, 47, 101342.	1.1	24
107	There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness. <i>American Journal of Preventive Cardiology</i> , 2022, 12, 100371.	1.3	23
108	Angiopietin-like 3: An important protein in regulating lipoprotein levels. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2023, 37, 101688.	2.2	10
109	Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	78
110	Nonviral Delivery of CRISPR/Cas Systems in mRNA Format. <i>Advanced NanoBiomed Research</i> , 2022, 2, .	1.7	8

#	ARTICLE	IF	CITATIONS
112	Qualitative development of the PROMIS Profile v1.0-Familial Chylomicronemia Syndrome (FCS) 28. Quality of Life Research, 0, , .	1.5	0
113	The Citrus Flavonoid Nobiletin Downregulates Angiopoietin-like Protein 3 (ANGPTL3) Expression and Exhibits Lipid-Modulating Effects in Hepatic Cells and Adult Zebrafish Models. International Journal of Molecular Sciences, 2022, 23, 12485.	1.8	5
114	Patterns of Lipid Lowering Therapy Use Among Older Adults in a Managed Care Advantage Plan in the United States. Journal of Pharmacy Practice, 2024, 37, 123-131.	0.5	0
115	A stepwise approach to prescribing novel lipid-lowering medications. Journal of Clinical Lipidology, 2022, 16, 822-832.	0.6	1
117	Relationship between blood glucose levels and length of hospital stay in patients with acute pancreatitis: An analysis of MIMIC-III database. Clinical and Translational Science, 2023, 16, 246-257.	1.5	3
118	Hypertriglyceridemia may contribute to stroke and pancreatitis: A case report and review of the literature. Frontiers in Endocrinology, 0, 13, .	1.5	0
119	Management of Familial Hypercholesterolemia with Special Emphasis on Evinacumab. Biomedicines, 2022, 10, 3273.	1.4	0
120	How ANGPTL3 Inhibition Will Help Our Clinical Practice?. Current Atherosclerosis Reports, 2023, 25, 19-29.	2.0	3
121	Atherosclerotic plaque regression in homozygous familial hypercholesterolaemia: a case report of a long-term lipid-lowering therapy involving LDL-receptor-independent mechanisms. European Heart Journal - Case Reports, 2022, 7, .	0.3	3
122	Broadening the Scope of Dyslipidemia Therapy by Targeting APOC3 (Apolipoprotein C3) and ANGPTL3 (Angiopoietin-Like Protein 3). Arteriosclerosis, Thrombosis, and Vascular Biology, 2023, 43, 388-398.	1.1	26
123	Evinacumab, an ANGPTL3 Inhibitor, in the Treatment of Dyslipidemia. Journal of Clinical Medicine, 2023, 12, 168.	1.0	7
124	New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3. Journal of Lipid and Atherosclerosis, 2023, 12, 23.	1.1	6
125	Monoclonal Antibodies, Gene Silencing and Gene Editing (CRISPR) Therapies for the Treatment of Hyperlipidemia—The Future Is Here. Pharmaceutics, 2023, 15, 459.	2.0	4
126	Clinical Trial Design for Triglyceride-Rich Lipoprotein-Lowering Therapies. Journal of the American College of Cardiology, 2023, 81, 1646-1658.	1.2	7
127	Proteome-Wide Mendelian Randomization Identifies Causal Links Between Blood Proteins and Acute Pancreatitis. Gastroenterology, 2023, 164, 953-965.e3.	0.6	9
128	What is really new in triglyceride guidelines?. Current Opinion in Endocrinology, Diabetes and Obesity, 2023, 30, 73-80.	1.2	0
129	ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases. Trends in Cardiovascular Medicine, 2023, , .	2.3	16
130	Lipid metabolism and the targeting of angiopoietin-like 3: Experimental drugs under development. Expert Opinion on Investigational Drugs, 2023, 32, 177-180.	1.9	0

#	ARTICLE	IF	CITATIONS
131	Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial. <i>Nature Medicine</i> , 2023, 29, 729-737.	15.2	22
134	Evinacumab-dgnb (Evkeeza-REGN1500), A Novel Lipid-Lowering Therapy for Homozygous Familial Hypercholesterolemia. <i>Cardiology in Review</i> , 2024, 32, 180-185.	0.6	0
137	Production and Metabolism of Triglyceride-Rich Lipoproteins: Impact of Diabetes. <i>Contemporary Diabetes</i> , 2023, , 169-194.	0.0	0
138	Special Patient Populations. , 2024, , 375-382.e2.		0
139	Special Patient Populations. , 2024, , 287-297.e2.		0
140	Inhibition of ANGPTL3 as a Target for Treating Dyslipidemias. , 2024, , 253-267.e1.		0
158	Inhibition of Angiotensin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia. <i>Current Atherosclerosis Reports</i> , 2023, 25, 1101-1111.	2.0	3
159	How to Handle Elevated Triglycerides: Life after PROMINENT. <i>Current Atherosclerosis Reports</i> , 2023, 25, 921-929.	2.0	1
160	Using ICD9/10 codes for identifying ADPKD patients, a validation study. <i>Journal of Nephrology</i> , 0, , .	0.9	0
162	RNA interference-based therapies for atherosclerosis: Recent advances and future prospects. <i>Progress in Molecular Biology and Translational Science</i> , 2024, , 1-43.	0.9	0